SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Renault PF, Hoofnagle JH, Park Y et al. Psychiatric complication of long-term alpha therapy. Arch. Intern. Med. 1987; 147: 1577 1580.
  • 2
    Nozaki O, Takagi C, Takaoka K, Takata T, Yoshida M. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C. An overview of cases in Japan. Psychiatry Clin. Neurosci. 1997; 51: 175 180.
  • 3
    Renault PF & Hoofnagle JH. Side effects of alpha interferon. Semin. Liver Dis. 1989; 9: 273 277.
  • 4
    Prasad S, Walters B, Hill FB, Portera FA, Riely CA. Psychiatric side effects of interferon alpha-2b in patients treated for hepatitis C. Clin. Res. 1992; 40: 840A.
  • 5
    Janssen HL, Brouwer JT, Van Der Mast RC, Mast RC, Schalm SW. Suicide associated with alpha-interferon therapy for chronic viral hepatitis. J. Hepatol. 1994; 21: 241 243.
  • 6
    Hosoda S, Takimura H, Shibayama M et al. Treatment of depressive state induced by interferon in patients with chronic hepatitis type C. Clin. Gastroenterol. 1995; 10: 1717 1722 (in Japanese).
  • 7
    Hosoda S, Takimura H, Shibayama M et al. Antidepressant drug treatment of depressive state induced by interferon in patients with active chronic hepatitis; clinical evaluation of efficacy of trazodone hydrochloride. Clin. Psychiatry 1997; 39: 291 299 (in Japanese).
  • 8
    Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systematically administered interferon-alpha. Neurology 1991; 41: 672 676.
  • 9
    Horiguchi J, Jitsuiki H, Kozuru T, Yokota N, Yamawaki S. A case of chronic hepatitis type C with irreversible Parkinsonism induced probably by interferon treatment. Clin. Psychiatry 1996; 38: 1227 1229 (in Japanese).
  • 10
    Kashima N, Asada T, Kimura M, Uno M, Takahasi K. A case of prolonged dementia induced by interferon therapy. Clin. Psychiatry 1998; 40: 401 406 (in Japanese).
  • 11
    Monji A, Yoshida I, Tashiro K, Hayashi Y, Tashiro S. Two cases of chronic hepatitis C with persistent affective disorders induced interferon treatment. Clin. Psychiatry 1998; 40: 649 651 (in Japanese).
  • 12
    Fuse Y, Kimura T, Yoshihara M. Panic attacks, and prolonged anxiety and depressive state associated interferon administration. Clin. Psychiatry 1998; 40: 767 768 (in Japanese).
  • 13
    Nishikawa T, Ikejiri Y, Kiyotaki C, Takeda M. The prominent effect of bromocriptine on a persistent depression induced interferon α. Jpn. J. Psychiatr. Treatment 1999; 14: 1105 1109 (in Japanese).
  • 14
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington DC, 1994.
  • 15
    Mehta CR & Patel NR. A network algorithm for performing Fisher's exact test in rxc contingency tables. JASA 1983; 78: 427 434.
  • 16
    Otsubo T, Miyaoka H, Kamijima H, Onuki M, Ishii M, Mitamura K. Depression during interferon therapy in chronic hepatitis C patients: A prospective study. Seishin Shinkeigaku Zasshi 1997; 99: 101 127 (in Japanese).
  • 17
    Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26: 112s 121s.
  • 18
    Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K. A controlled study to determine the optimal dose regimen of interferon-alfa 2b in chronic hepatitis C. Am. J. Gastroenterol. 1995; 90: 1246 1249.
  • 19
    Iino S. The Side Effects of Interferon in the Study of Specific Disease. The Health and Welfare Ministry of Japan, Tokyo, 1993 (in Japanese).
  • 20
    Okanoue T, Sakamoto S, Itoh Y et al. Side effects high dose interferon therapy for chronic hepatitis C. J. Hepatol. 1996; 25: 283 291.
  • 21
    Fattovich G, Giustina G, Facarato S, Ruol A. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol. 1996; 24: 38 47.
  • 22
    Otsubo T, Miyaoka H, Kamijima H, Ishii M, Onuki M, Mitamura K. Depression during interferon therapy among c-type chronic hepatitis patients: A prospective study. Clin. Psychiatry 1994; 36: 768 770 (in Japanese).
  • 23
    Van Thiel DH, Friedlander L, Molly PJ et al. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur. J. Gastroenterol. Hepatol. 1995; 7: 165 168.
  • 24
    Liberati AM, Biagini S, Perticoni G et al. Electrophysiological and neurophysiological functions in patients treated with interferon-β. J. Interferon Res. 1990; 10: 613 619.
  • 25
    Dunn AJ. Interactions between the nervous system and the immune system: Implications for psychopharmacology. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology. Raven Press, New York, 1994; 719 731.
  • 26
    Levenson JL & Fallon HJ. Fluoxetine treatment of depression caused by interferon-α. Am. J. Gastroenterol. 1993; 88: 760 761.
  • 27
    Demitrack MA, Dale JK, Straus SE et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J. Clin. Endocrinol. Metab. 1991; 73: 1224 1234.
  • 28
    Felten DL, Cohen N, Ader R, Felten SY, Carlson SL, Roszman TL. Central Neural circuit involved in neural–immune interactions. In: Ader R, Cohen N (eds). Psychoneuroimmunology, 2nd edn. Academic Press, San Diego, 1991; 3 25.
  • 29
    Bocci V. Central nervous system toxicity of interferons and other cytokines. J. Biol. Regul. Homeost. Agents 1988; 2: 107 118.
  • 30
    Balock JE & Smith EM. Human leukocyte interferon (IFN-α) potent endorphin-like opioid activity. Biochem. Biophys. Res. Commun. 1981; 101: 472 478.